# ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct01360554/  
OnCo record `nct01360554` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dacomitinib and Erlotinib in Non-small-cell lung cancer, run by Pfizer, completed.

## Summary

ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT01360554 by Pfizer, with 878 participants recorded, started 2011-06-16 and reaching its primary completion in 2013-09-30. Interventions recorded: Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804. Conditions recorded: Non-Small Cell Lung Cancer.

Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01360554
- Phase: 3
- Setting: Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy
- Sponsor: Pfizer
- Enrolled: 878

## Sources

- ClinicalTrials.gov NCT01360554: https://clinicaltrials.gov/study/NCT01360554

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Dacomitinib](https://onco.cc/drugs/dacomitinib/), [Erlotinib](https://onco.cc/drugs/erlotinib/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct01360554.json